

HORIZON PHARMA, INC.  
Form 8-K  
March 28, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 28, 2012

**Horizon Pharma, Inc.**

(Exact name of registrant as specified in its charter)

Delaware  
(State of incorporation)

001-35238  
(Commission File No.)  
520 Lake Cook Road, Suite 520,

27-2179987  
(IRS Employer Identification No.)

Edgar Filing: HORIZON PHARMA, INC. - Form 8-K

**Deerfield, Illinois 60062**

(Address of principal executive offices and zip code)

**Registrant's telephone number, including area code: (224) 383-3000**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On March 28, 2012, we filed suit in the United States District Court for the District of Delaware against Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc. (collectively, Par ). The lawsuit alleges that Par has infringed U.S. Patent No. 8,067,033 (the 033 patent ) by filing an Abbreviated New Drug Application ( ANDA ) seeking approval from the U.S. Food and Drug Administration ( FDA ) to market a generic version of DUEXIS® tablets prior to the expiration of the patent. The 033 patent is listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Our commencement of the patent infringement lawsuit stays, or bars, FDA approval of Par's ANDA for 30 months or until an earlier district court decision that the 033 patent is not infringed or invalid.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 28, 2012

Horizon Pharma, Inc.

By: /s/ Robert J. De Vaere  
Robert J. De Vaere  
Executive Vice President and Chief Financial Officer